From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Therapeutic Advances in Medical Oncology

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: A multicenter real-world study

Journal of Managed Care and Specialty Pharmacy

Economic value of ribociclib in early breast cancer in the United States

Tumori

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Lancet Regional Health

Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy

Annals of Oncology

Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Annals of Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: Final overall survival analysis of the phase 3 TROPION-Breast01 study

eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Biomedicines

Cryotherapy as a surgical de-escalation strategy in breast cancer: Techniques, complications, and oncological outcomes

Cancers

HER2-low and HER2-ultralow metastatic breast cancer and trastuzumab deruxtecan: Common clinical questions and answers

Breast Cancer Research and Treatment

Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression

The Breast

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: Balancing oncologic benefit and surgical safety

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

The American Surgeon

Assessing nodal positivity in men 70 years of age and older with clinically node negative hormone-receptor positive breast cancer to guide axillary intervention

The Breast

Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Breast Cancer Research

Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread

Cancer Research and Treatment

Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

Journal of Surgical Oncology

Do racial and income disparities exist in the application of 21-gene recurrence score?

JAMA Oncology

Vaginal estrogen therapy use and survival in females with breast cancer

Journal of Clinical Oncology

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Cancers

CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

Science Progress

Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence

Journal of Clinical Oncology

Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

The Breast

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer

Journal of Clinical Oncology

The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer

Journal of Clinical Oncology

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

Journal of Clinical Oncology

Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

Seminars in Nuclear Medicine

AI in breast cancer imaging: An update and future trends

Journal of Clinical Oncology

Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Frontiers in Oncology

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review

Radiographics

Breast cancer surveillance in patients with a personal history of breast cancer: Updates and controversies

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Future Oncology

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

Cancer Letters

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

Nature Communications

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Drugs

Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2- early breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: The first case report for combination efficacy and safety

The Journal of Pathology. Clinical Research

High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Clinical evidence from a large-scale, multiple-site, retrospective study

Clinical Breast Cancer

Real world evidence study to assess incidence, treatment patterns, clinical outcomes, and health care resource utilization in early-stage, high-risk HER2-negative breast cancer in Alberta, Canada

Oncology Research and Treatment

Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany: Final results of the phase 2 multicohort INGE-B trial

Therapeutic Advances in Medical Oncology

Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

Cureus

Dormancy leading to late recurrence in breast cancer: A case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment

Frontiers in Immunology

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions

Clinical Cancer Research

Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

Frontiers in Immunology

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

American Journal of Clinical Oncology

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

npj Breast Cancer

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

JHEP Reports

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment

JAMA Surgery

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial

Future Oncology

The NEOLETRIB trial: Neoadjuvant treatment with letrozole and ribociclib in ER-positive, HER2-negative breast cancer

Anticancer Research

Risk factors for non-sentinel lymph node metastasis in HR+/HER2- breast cancer with cN0

Radiology Case Reports

Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+/HER2- breast cancer: A case report

Reviews in Cardiovascular Medicine

Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis

Oncology and Therapy

Palbociclib in HR-positive, HER2-negative advanced/metastatic breast cancer: A systematic scoping review of real-world evidence from countries outside of Western regions that are underrepresented in clinical trials

Journal of Clinical Medicine

Novel treatment strategies for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer

Cancers (Basel)

Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer

Current Opinion in Oncology

Controversies on chemotherapy for early HR+/HER2- breast cancer: The role of anthracyclines and dose intensification

npj Breast Cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Managing Adverse Events for Women Receiving Adjuvant Breast Cancer Treatment

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer